KRAS and colorectal carcinoma: In metastatic CRC with non-mutated KRAS status, a relationship between an elevated telomere length and a good response (inhibition of proliferation) to anti-EGFR has recently been observed, without, however, any relationship between KRAS status and telomere length [44].